Welcome to our dedicated page for Pulse Biosciences news (Ticker: $PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pulse Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pulse Biosciences's position in the market.
News
Rhea-AI Summary
Pulse Biosciences (PLSE) filed a premarket notification 510(k) to the U.S. FDA for its CellFX nsPFA percutaneous electrode, designed for non-cardiac applications. The filing was made earlier than expected, showcasing the efficiency of the FDA's new electronic submission platform. The FDA will conduct its substantive review, with a goal to complete it within 90 calendar days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.59%
Tags
-
Rhea-AI Summary
Pulse Biosciences, Inc. (PLSE) to Present at 35th Annual Piper Sandler Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
-
Rhea-AI Summary
Pulse Biosciences (PLSE) to host Third Quarter 2023 Financial Results conference call on November 13, 2023. The company reported advancements in cardiac ablation technology, appointment of a renowned cardiothoracic surgeon, and positive results from thyroid clinical feasibility study. Financially, GAAP and non-GAAP costs and expenses decreased compared to the prior year period. Cash and cash equivalents totaled $50.4 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.84%
Tags
News
Rhea-AI Summary
Pulse Biosciences, Inc. (PLSE) to Host Conference Call and Report Q3 2023 Financial Results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Pulse Biosciences (PLSE) will report Q3 2023 financial results on November 13, 2023, after market close. The company focuses on using its nsPFA technology for the treatment of atrial fibrillation. A conference call will be held at 1:30pm PT / 4:30pm ET, and a webcast will be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
-
Rhea-AI Summary
Pulse Biosciences announces the appointment of Dr. Niv Ad as Chief Science Officer, Cardiac Surgery. Dr. Ad believes that the company's nsPFA technology has the potential to replace other energy modalities in cardiac ablation and significantly expand the number of patients treated in cardiac surgery. His expertise will contribute to the development of the company's product portfolio for cardiac surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
Rhea-AI Summary
Pulse Biosciences collaborates with CardioNXT to support first-in-human study on atrial fibrillation treatment using nsPFA technology. Integration of nsPFA catheter with CardioNXT's iMap system offers superior accuracy and stability. First-in-human study to begin in H1 2023. Positive potential for best-in-class clinical outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
-
Rhea-AI Summary
Pulse Biosciences' nsPFA technology to be featured at Global EP Summit 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.57%
Tags
-
Rhea-AI Summary
Pulse Biosciences announces positive results from a clinical feasibility study on nsPFA technology for treating benign thyroid tumors or nodules. The study shows complete ablation of cellular tissue without damage to noncellular structures. The findings suggest that nsPFA could be a significant advancement in treatment, with advantages including cellular tissue selectivity, sharp ablation zone margins, absence of thermally induced necrosis, and short treatment times.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
Rhea-AI Summary
Pulse Biosciences to present at Gilmartin Group Emerging Growth Showcase on Sept 21, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
Pulse Biosciences, Inc
Nasdaq:PLSE
PLSE Rankings
PLSE Stock Data
431.86M
16.31M
70.38%
8.07%
4.76%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
HAYWARD
About PLSE
pulse biosciences, inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary nano-pulse stimulation (nps) technology. nps is a non-thermal, drug-free energy-based technology that can stimulate unique behaviors in cells by applying ultra-short nanosecond (billionths of a second) electrical pulses that affect the cell membrane and intracellular structures. these cell effects influence cell regulation functions and can lead to unique immune system responses. pulse biosciences is investigating a variety of applications for its nps technology that exploits its unique biologic effect, including immuno-oncology and dermatology. pulse biosciences, inc. (plse, nasdaq) corporate headquarters is located in hayward, ca. ~ our mission ~ to build a viable company that designs, produces, and commercializes nano-pulse technology to improve and extend the lives of patients to solve the needs of patients, physicians, and